Company Overview and News
Suresh P Iyengar Sanjay Swaroop, a conservative mutual fund investor from Odisha, was surprised when the words ‘credit risk’ suddenly cropped up in two of the mutual fund schemes he had invested in, thinking they were as safe as recurring deposits at banks.
HDFC Mutual Fund has sought the Securities and Exchange Board of India's approval for its HDFC Ultra Short Term Fund, according to the draft offer document available on the regulator's website.
HDFC Mutual Fund will discontinue subscriptions and systematic investments in HDFC Long Term Advantage Fund with effect from May 16, the fund house said in an addendum.
In the week gone by, ICICI Bank and Axis Bank remained the buzz word with the controversies surrounding the leaders of these banks.
AXBKY HDFCNIFETF AXBA ICICIBANK AXB AXISBANK 532174 IBN 539516 532215
Suresh P Iyengar Thanks to the ‘Mutual Funds Sahi Hain’ campaign, the industry seems to have hit the right growth trajectory even as uncertainty looms large on the growth prospects of the economy and corporate earnings.
HDFCNIFETF 500710 AKZOINDIA 539516
HDFC Mutual Fund will introduce HDFC Flex systematic investment plan for investments under the growth option plan of open-ended equity and balanced funds, with effect from April 3, the mutual fund house said in an addendum.
IDFC Asset Management Company is up for sale, and may soon be acquired by another large mutual fund player or a company as the AMC’s parent, IDFC is looking to exit the AMC business.
STAN 532938 INDUSINDBK CAPF 539516 539437 HDFCNIFETF 532187 IDFCBANK 580001 STAB STAN STAC 2888 SCBFF
Our Bureau Housing Development Finance Corporation, a mortgage lending firm, has decided to offload a little over 4 per cent of its holding in its subsidiary HDFC Asset Management Company through an initial public offering.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...